Jun 25, 2020
The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 equally role of a commitment to innovation in Neuroscience to identify and encourage technology ideas from all over the earth with the aim to ameliorate mobility, accessibility and daily life for people living with MS
Canadian visitor AccessNow receives the first prize
for a mobile app and web platform that provides information about the accessibility status for people with disabilities of locations around the world, enabling them to move around with more confidence and ease
Runner-upwardly receiving USD 50,000 is the start-upward Fly Parrots from the United States who developed Polly, a socially assistive robot with an inclusive convenient app so people with mobility and communication challenges tin connect better with the world
To back up pioneering solutions for increased mobility and accessibility, Novartis worked with
WIRED Brand Lab, aslope other primal collaborators such as Selma Blair, representatives from Sequoia, Airbnb, Whill, Shift.ms, the National Multiple Sclerosis Order, and people living with MS
Basel, June 25, 2020
— “It is such an honor to exist awarded the Novartis Innovation Prize. Accessibility is a critical component of establishing a welcoming and barrier-complimentary world for people with disabilities, including those living with MS,” said Maayan Ziv, Founder and CEO AccessNow. “Nosotros accept come a long way, but we have so much more to do to accomplish equity and inclusion. At AccessNow we believe technology plays an integral office in achieving this vision and nosotros are then excited for the next step in our journeying.”
The runner-up is an intelligent plug-and-play device and app called Polly. It empowers people with mobility and communication challenges to exist more connected with the world around them through features similar prophylactic navigation, 360-reckoner vision, smart dwelling house connectivity and more.
“The Novartis Innovation Prize represents a slap-up opportunity to aid the world understand the touch on of living with multiple sclerosis, but likewise to explore how technology and innovation facilitates mobility and fosters connection for the MS community,” said Tim Coetzee, Chief Advocacy, Services, and Research Officer, National MS Society and a prize judge. “It is inspiring to see the patient customs, innovators, venture capital, large tech companies, and loftier affect technology come together and showcase the potential to improve the daily lives of those living with MS or other disabilities. Sustained collaboration and innovation in these diverse sectors are vital to ensure that the needs of these communities are being met.”
More information about the Novartis Innovation Prize winners and finalists is available at www.wired.com/msinnovationprize.
Almost the Innovation Prize
The Novartis Innovation Prize: Assistive Tech for MS identifies and embraces technology that aims to better the mobility, accessibility and activities of daily life for these individuals and others living with mobility-limiting atmospheric condition. Applications were open up to the tech customs, innovators, blueprint experts and patient advocates worldwide — anyone with an idea to make everyday life amend for those with MS or other mobility-limiting atmospheric condition. The prize judging panel consisted of a wide variety of experts including accessibility leaders, representatives from the MS patient community, investors, and consumer technology experts within the mobility and healthcare infinite.
Well-nigh Multiple Sclerosis
MS disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss1. MS, which affects approximately 2.3 million people worldwideii, is often characterized into three forms: primary progressive MS (PPMS)3, relapsing remitting MS (RRMS), and secondary progressive MS (SPMS), which follows from an initial RRMS course and is characterized by physical and cerebral changes over fourth dimension, in presence or absence of relapses, leading to a progressive aggregating of neurological disability4. Approximately 85% of patients initially present with relapsing forms of MStwo.
This media update contains forwards-looking statements within the meaning of the U.s.a. Individual Securities Litigation Reform Act of 1995. Forward-looking statements can by and large be identified by words such as “potential,” “can,” “will,” “program,” “may,” “could,” “would,” “wait,” “anticipate,” “seek,” “look forwards,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or past express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You lot should not identify undue reliance on these statements. Such forward-looking statements are based on our electric current beliefs and expectations regarding future events, and are field of study to meaning known and unknown risks and uncertainties. Should 1 or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, bodily results may vary materially from those set forth in the forrad-looking statements. There can be no guarantee that the investigational or canonical products described in this media update will be submitted or approved for auction or for any additional indications or labeling in any market, or at any particular time. Nor can there be whatsoever guarantee that such products will exist commercially successful in the future. In particular, our expectations regarding such products could be affected past, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or authorities regulation generally; global trends toward wellness care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the detail prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; prophylactic, quality, data integrity or manufacturing issues; potential or actual information security and data privacy breaches, or disruptions of our it systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the Usa Securities and Commutation Commission. Novartis is providing the data in this media update as of this appointment and does not undertake any obligation to update any forward-looking statements independent in this media update as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’southward lives. Every bit a leading global medicines company, we use innovative scientific discipline and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank amongst the world’s elevation companies investing in research and evolution. Novartis products reach nigh 800 one thousand thousand people globally and nosotros are finding innovative ways to expand access to our latest treatments. Almost 109,000 people of more than 145 nationalities piece of work at Novartis around the globe. Notice out more at
Novartis is on Twitter. Sign upwards to follow @Novartis at
For Novartis multimedia content, please visithttps://world wide web.novartis.com/news/media-library
For questions well-nigh the site or required registration, please contact
[electronic mail protected]
1. National Multiple Sclerosis Society.
Definition of MS. https://world wide web.nationalmssociety.org/What-is-MS/Definition-of-MS. Accessed May 2020.
ii. Multiple Sclerosis International Federation.
Atlas of MS 2013. Mapping Multiple Sclerosis Around the World. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed May 2020.
iii. MS Society.
Types of MS. https://world wide web.mssociety.org.uk/about-ms/types-of-ms. Accessed May 2020.
4. National Multiple Sclerosis Society.
Secondary Progressive MS (SPMS). https://world wide web.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS. Accessed May 2020.
# # #
Novartis Media Relations
[electronic mail protected]
Novartis External Communications
+41 79 723 3681 (mobile)
Novartis Global Pharma Communications
+41 79 123 7806 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
|+41 61 324 8425
+41 61 324 7188
|Cory Twining||+1 862 778 3258|